

29th Annual Meeting

of the National Reference Laboratories for Avian Influenza
and Newcastle Disease of European Union Member States



Parma
2-3 October 2023

An update on molecular detection methods




Valentina Maria Panzarin
EURL AI-ND,
IZSVe - Laboratory of Innovative Virology



Development and validation of an array of RT-qPCR for the molecular pathotyping of APMV-1




Diagnostic workflow for APMV-1 at EURL






Diagnostic workflow for APMV-1 at EURL



Set up of the array of RT-qPCR targeting the F gene



Source:
Dimitrov et al., 2019



common primers
1 probe **avirulent**
1 probe **virulent**



incl. PPMV-1

incl. vaccine strains




Pathotyping in dual mode

Source:
Dimitrov et al., 2019




RT-qPCR product can undergo Sanger sequencing to obtain the CS sequence



Validation pathway

Source:
WOAH Terrestrial Manual 2023





Stage 1 – analytical validation

1. Analytical sensitivity

> 1log compared to
Sutton 2019

2. Repeatability

Strain spiked in lung homogenate	Genotype	Set	LoD EID ₅₀ /100 µl	%E	R ²	%CV
APMV-1 Ulster*	I	A (Avir)	10 ^{1.5}	95.67	0.996	n.a.
APMV-1 V4 like*	I	A (Avir)	10 ^{1.5}	98.50	0.986	≤ 4.2
APMV-1 VG/GA*	I.1.1	A (Avir)	10 ^{1.83}	105.10	0.982	n.a.
APMV-1 B1*	II	A (Avir)	10 ^{1.5}	103.68	0.982	n.a.
APMV-1 LaSota*	II	A (Avir)	10 ^{2.83}	108.30	0.981	n.a.
APMV-1 Herts	IV	A (Vir)	10 ^{1.62}	95.24	0.889	≤ 4.4
APMV-1/chicken/California/18-016505-1/2018	V.1	A (Vir)	10 ^{4.62}	80.83	0.872	≤ 6.5
PPMV-1/pigeon/Italy/19vir8321/2019	VI.2.1.1.2.2	B (Vir)	10 ¹	100.60	0.892	≤ 6.7
APMV-1/bassette chicken/Belgium/4096/2018	VII	B (Vir)	10 ^{1.62}	108.41	0.972	n.a.
APMV-1/chicken/rus/Krasnodar/9.1/2019	VII.1.1	B (Vir)	10 ^{2.62}	92.81	0.996	n.a.
APMV-1/Macedonia/20VIR1984-1/2020	VII.2	B (Vir)	10 ^{1.5}	108.30	0.996	n.a.
APMV-1/chicken/Nigeria/4TACK15-18T_21RS744-46/2020	XIV.2	B (Vir)	10 ^{2.62}	80.15	0.960	n.a.
APMV-1/chicken/Camerun/3490-168/2008	XVII	B (Vir)	10 ^{2.83}	90.65	0.969	n.a.
PPMV-1/pigeon/Luxembourg/18175752/2018	XXI.1.1	B (Vir)	10 ^{2.62}	88.50	0.942	n.a.
APMV-1/avian/Bulgaria/11VIR1897/2011	1	C (Avir)	10 ^{1.7}	81.07	0.990	≤ 2.9

3. Analytical specificity

Inclusivity verified for isolates representing genotypes I, II, VI, VII, XIII, XIV, XVIII, XXI
 No cross-reaction with matrix components or non-target avian viruses


Stage 2 – diagnostic validation

67 APMV-1 negative


59 APMV-1 positive of genotypes I, II, VI, VII, XIII, XIV, XVIII, XXI

- Organs, swabs, FTA from Europe, Africa, Middle East, Asia
- Assessment in parallel with Sutton 2019 and Kant 1997

Pathotyping by vir/avir probes



Pathotyping by sequencing RT-qPCR products





Stage 3 - reproducibility




FRIEDRICH-LOEFFLER-INSTITUT

FLI

NATIONAL
VETERINARY
INSTITUTE

Bundesforschungsinstitut für Tiergesundheit
Federal Research Institute for Animal Health

1. Reproducibility study with 3 participants: Fleiss kappa 0,88



Ramp/rate affects assay performance

Slower rates are recommended

2. EQA provided by the FLI (self assessment): Cohen kappa 1



Recommendations for use of the new RT-qPCR array

Rapid method to discriminate virulent and avirulent APMV-1 in dual mode (probes and Sanger sequencing)

- Optimization is required if using different reagents/equipment
- Sanger can be optional in samples yielding $Cq \leq 35$ (cost-benefit considerations on time, costs, equipment)
- Sanger needs to be performed for samples yielding $Cq > 35$
- Potential as a DIVA strategy
- More validation data are required for strains from Asia and America and for genotypes unavailable at the EURL AI/ND
- Will this method replace SOP VIR 1002 and 063? We don't know!
- Periodic reassessment of oligonucleotides will be needed

— All details available here



Journal of Virological Methods

Available online 16 September 2023, 114813

In Press, Journal Pre-proof What's this?



A novel array of real-time RT-PCR assays for the rapid pathotyping of type I avian paramyxovirus (APMV-1)

Andrea Fortin^{a e} , Andrea Laconi^b , Isabella Monne^a , Siamak Zohari^c ,
Kristofer Andersson^c , Christian Grund^d , Mattia Cecchinato^e ,
Marika Crimaudo^a , Viviana Valastro^a , Valeria D'Amico^a ,
Alessio Bortolami^a , Michele Gastaldelli^a , Maria Varotto^a ,
Newcastle Disease Collaborating Diagnostic Group¹, Calogero Terregino^a ,
Valentina Panzarini^a

Soon, the procedure SOP VIR 1006 also in
the EURL website..



Updates on diagnostic methods available in the EURL webpage

Updates on diagnostic methods

SOP VIR 1000 (sample preparation and NA extraction)

Validation of IndiMag Pathogen KF96 Cartridge (Indical Bioscience)


SOP VIR 151 (APMV-1 screening)

Unsuitability of the MagMax Pathogen RNA/DNA Kit (Applied Biosystems) for organs/tissues

SOPs VIR 018, 125, 143, 1004 (AIV screening and H5 detection)

Application extended to mammalian samples processing

Surveillance in human exposed to H5 HPAI



SOP VIR 1004 (AIV HA and NA subtyping)

Update of the oligonucleotides set for H13 detection

N2: RITA1 is recommended in place of RITA2

N6: issues with the RITA2 probe → James et al. is recommended instead

N5, N7, N8, N9: RITA2 as a first choice. James et al. provided as a second try

Updates on diagnostic methods

SOP VIR 1000 (sample preparation and NA extraction)

Validation of IndiMag Pathogen KF96 Cartridge (Indical Bioscience)

The information in this document is subject to change without notice.

Revision history

Revision	Date	Description
ed. 02	September 2023	<ul style="list-style-type: none">Application extended to mammalian samples processingInterpretation of resultsRemoval of primer H13-F3 and update of H13 oligonucleotides concentrationMinor edits for clarity, style and consistency
ed. 01	July 2023	<ul style="list-style-type: none">Updated referencesUpdated oligonucleotides sets, reaction volume and cycling conditionsInclusion of assays for H5 and H7 subtypes detectionInclusion of the internal control (optional) for the H5 and H7 assaysMinor edits for style and consistency
ed. 00	April 2021	Initial release

systems) for organs/tissues



N6: issues with the RITA2 probe → James et al. is recommended instead

N5, N7, N8, N9: RITA2 as a first choice. James et al. provided as a second try

Thanks for the attention, and for keep on sharing with us
viruses, sequences and issues that help us improve
diagnostic methods

Andrea



vpanzarin@izsvenezie.it